NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.375
+0.035 (2.61%)
Jun 29, 2026, 3:21 PM EDT - Market open
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,155,856
Market Cap
31.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| Kyntra Bio | 34 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| Daré Bioscience | 24 |
| Lisata Therapeutics | 21 |
| Tevogen Bio Holdings | 18 |
| Barinthus Biotherapeutics | 14 |
NNVC News
- 6 hours ago - NanoViricides granted Rare Pediatric Disease Drug designation for NV-387 - TheFly
- 6 hours ago - US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher - Accesswire
- 7 days ago - NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo - TheFly
- 7 days ago - NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo - Accesswire
- 13 days ago - NanoViricides files to sell 1.33M shares of common stock for holders - TheFly
- 14 days ago - NanoViricides announces proposal approved by Pillar Committee in DRC - TheFly
- 14 days ago - As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo - Accesswire
- 21 days ago - NanoViricides proposes Phase II trial of NV-387 gummies in Ebola - TheFly